◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

BridgeBio Pharma Inc (BBIO) EBITDA 2017–TTM

Name: BridgeBio Pharma Inc (BBIO) ebitda history 2017-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

BridgeBio Pharma Inc annual ebitda for fiscal 2025 was -$673 million, a decrease of 54.0% from -$437 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

BBIO Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
EBITDA	—	($673M)	($437M)	($565M)	($397M)	($534M)	($467M)	($279M)	($183M)	($44M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BBIO Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	—	($113M)	($180M)	($173M)	($143M)	($126M)	($235M)	($140M)	($51M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

JAZZ EBITDA — Jazz Pharmaceuticals PLC
ASND EBITDA — Ascendis Pharma AS
EXEL EBITDA — Exelixis Inc
SMMT EBITDA — Summit Therapeutics PLC
HALO EBITDA — Halozyme Therapeutics Inc
BMRN EBITDA — Biomarin Pharmaceutical Inc

More BBIO metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All BBIO financial statements → Interactive BBIO charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.